Application of cyclin protein G1

A protein and protein technology, applied in the biological field, can solve the problems that cannot fully reflect the biological characteristics of liver cancer, and the sensitivity and specificity of indicators are difficult to meet the clinical prediction requirements.

Inactive Publication Date: 2011-07-27
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current studies have found that CK19, HSP27, etc. can be used as potential predictors of liver cancer metastasis and recurrence, but the sensitivity and specificity of these indicators are still d

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cyclin protein G1
  • Application of cyclin protein G1
  • Application of cyclin protein G1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Sample: a tissue section of a liver cancer patient's tumor, and the relative expression of cyclin G1 protein in the liver cancer tissue was detected by the above-mentioned immunohistochemical method test steps. Micrographs of liver cancer tissue and paracancerous tissue image 3 shown. After calculation, the RG value is 3.60.

[0061] According to postoperative follow-up, the patient died 14 months after the operation, and the disease-free survival period was only 13 months.

Embodiment 2

[0063] Sample: a tissue section of a liver cancer patient's tumor, and the relative expression of cyclin G1 protein in the liver cancer tissue was detected by the above-mentioned immunohistochemical method test steps. Micrographs of liver cancer tissue and paracancerous tissue Figure 4 shown. After calculation, the RG value is 0.11.

[0064] According to postoperative follow-up, the patient survived for 60 months without disease, and was still alive at the end of the follow-up period.

Embodiment 3

[0066] Liver tissue was randomly removed from patients with liver cancer, and tissue slices of tumors from patients with liver cancer were prepared. The above immunohistochemical method was used to detect the relative expression of cyclin G1 protein in liver cancer tissues, and the RG value was calculated. According to the expression level of cyclin G1 (high expression if RG value is higher than 1.43, low expression if RG value is lower than 1.43), liver cancer patients are divided into groups, and the overall survival curve is drawn ( Figure 5 ) and disease-free survival curves ( Figure 6 ). The results showed that the patients with high expression of cyclin G1 in the tumor had significantly shorter overall survival and disease-free survival than those with low expression.

[0067] From the above test results, it can be known that detecting the relative expression of cyclin G1 protein molecule by immunohistochemical method can predict the risk of distant metastasis of hepa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of cyclin protein G1. Relative expression quantity of the cyclin protein G1 between tumor tissues and tissue adjacent to tumor is determined by utilizing an immunohistochemistry technology, picture taking by a microscope and computer image processing software, correlation between the relative expression quantity of the cyclin protein G1 and prognosis of postoperative patient with hepatocellular carcinoma is determined by combining postoperative follow-up visit information, the cyclin protein G1 can be applied to preparation of a protein molecule maker for judging the prognosis of the patient with liver cancer and has importance directive significance for postoperative monitoring and sequential treatment for patients with hepatocellular carcinoma.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to the application of a cyclin G1 protein, in particular to the application of a cyclin G1 protein as a protein molecular marker for judging the prognosis of liver cancer. Background technique [0002] Liver cancer is a tumor with a very high degree of malignancy and a very poor prognosis. Its incidence rate ranks sixth in the world, and its case fatality rate ranks third at 0.96, ranking first among all cancers. Therefore, it is known as the "king of cancer" ". In the clinical diagnosis and treatment of liver cancer, there is still no great progress in solving the difficult problems such as difficult early diagnosis, high recurrence and metastasis rate, lack of pertinence in treatment, and few innovative drugs and treatment methods at the source. [0003] Statistics show that the high metastasis recurrence rate after liver cancer surgery (5-year recurrence rate reaches 70%, small liver c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/577G01N33/574
Inventor 王红阳文文丁劲吴琨
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products